Keywords: amarin, multicell, sign, ms, drug, accord, uk-based

Amarin and Multicell sign MS drug R&D accord

Article | 09 January 2006

Print This

UK-based biotechnology firm Amarin says that it has completed a $275.0 million licensing deal with US group Multicell which grants the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in